| Literature DB >> 20103721 |
Andrea Lapucci1, Matteo Lulli, Amedeo Amedei, Laura Papucci, Ewa Witort, Federico Di Gesualdo, Francesco Bertolini, Gary Brewer, Angelo Nicolin, Annamaria Bevilacqua, Nicola Schiavone, Dominique Morello, Martino Donnini, Sergio Capaccioli.
Abstract
The human antiapoptotic bcl-2 gene has been discovered in t(14;18) B-cell leukemias/lymphomas because of its overexpression caused at a transcriptional control level by the bcl-2/IgH fusion gene. We were the first to disclose the post-transcriptional control of bcl-2 expression mediated by interactions of an adenine + uracil (AU)-rich element (ARE) in the 3'-UTR of bcl-2 mRNA with AU-binding proteins (AUBPs). Here, we identify and characterize zeta-crystallin as a new bcl-2 AUBP, whose silencing or overexpression has impact on bcl-2 mRNA stability. An increased Bcl-2 level observed in normal phytohemagglutinin (PHA)-activated T lymphocytes, acute lymphatic leukemia (ALL) T-cell lines, and T cells of patients with leukemia in comparison with normal non-PHA-activated T lymphocytes was concomitant with an increase in zeta-crystallin level. The specific association of zeta-crystallin with the bcl-2 ARE was significantly enhanced in T cells of patients with ALL, which accounts for the higher stability of bcl-2 mRNA and suggests a possible contribution of zeta-crystallin to bcl-2 overexpression occurring in this leukemia.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20103721 PMCID: PMC2874474 DOI: 10.1096/fj.09-140459
Source DB: PubMed Journal: FASEB J ISSN: 0892-6638 Impact factor: 5.191